CN104998185A - Traditional Chinese medicine composition for treating gastrointestinal disease - Google Patents
Traditional Chinese medicine composition for treating gastrointestinal disease Download PDFInfo
- Publication number
- CN104998185A CN104998185A CN201510502780.4A CN201510502780A CN104998185A CN 104998185 A CN104998185 A CN 104998185A CN 201510502780 A CN201510502780 A CN 201510502780A CN 104998185 A CN104998185 A CN 104998185A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- fructus
- parched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating gastrointestinal disease. The traditional Chinese medicine composition comprises the following substances in parts by weight: 120-180 parts of cuttlefish bone, 120-150 parts of stir-baked rhizoma corydalis, 10-15 parts of rhizoma cimicifugae, 6-10 parts of radix dichroae, 30-45 parts of caramel malt, 30-45 parts of parched hawthorn fruit, 30-45 parts of stir-baked massa fermentata medici-nalis, 10-18 parts of bletilla striata, 200-250 parts of pollen pini, 15-20 parts of fructus amomi, 8-15 parts of pseudo-ginseng, 10-18 parts of poria cocos, 20-35 parts of roud cardamon seeds, 10-15 parts of dried tangerine peel, 15-25 parts of semen raphani, 30-50 parts of astragalus membranaceus, 120-150 parts of endothelium corneum gigeriae galli, 130-140 parts of stir-baked rhizoma atractylodis macrocephalae, 30-50 parts of polyporus umbellatus, 20-40 parts of fructus mume, 5-8 parts of rheum officinale, 20-40 parts of rhizoma cyperi, 60-80 parts of cortex ilicis rotundae, 20-30 parts of licorice and 200-400 parts of fructus jujubae. According to the traditional Chinese medicine composition for treating gastrointestinal disease, provided by the invention, all the substances have a mutual and synergistic effect, the curative effect is remarkable, and vigorous popularization is much worthwhile.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of Chinese medicine composition for the treatment of gastrointestinal disease.
Background technology
Modern medicine study shows, the gastrointestinal dysfunction overwhelming majority is the activity due to overworked, nervous, bad inter personal contact, the factor such as badly off interference higher nerve, affects vegetative nerve function and causes.Stagnation of liver-QI is the fundamental mechanism of gastrointestinal motility disorder, and during stagnation of liver-QI, digestive tract power is low, and changes with gut hormone level.The relation of modern study liver and taste, how from vegetative nerve function, urine xylose excretion rate, plasma cyclic nucleotide cAMP, cGMP measure, and Determination of Blood Rheology, the aspects such as small intestinal D-xylose absorbance and neuroimmunology are studied.But these all well can not disclose physiology, pathological relation between liver and taste.Gastrointestinal motility is one of critical function of taste, and it is that periodically generation electrical activity and mechanical activity have also been coordinated mutually by the smooth muscle at each position.Gastrointestinal motility is again very easily by the impact of emotion.Therefore relation between liver and taste can be studied with the change of gastrointestinal motility.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of gastrointestinal disease.
In order to realize object of the present invention, the invention provides a kind of Chinese medicine composition for the treatment of gastrointestinal disease, it comprises the material of following weight portion: Os Sepiae 120-180 part, Rhizoma Corydalis 120-150 part processed, Rhizoma Cimicifugae 10-15 part, Radix Dichroae 6-10 part, Fructus Hordei Germinatus (parched to brown) 30-45 part, Fructus Crataegi (parched to brown) 30-45 part, Massa Medicata Fermentata (parched to brown) 30-45 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 10-18 part, Pollen Pini 200-250 part, Fructus Amomi 15-20 part, Radix Notoginseng 8-15 part, Poria 10-18 part, roud cardamon seed 20-35 part, Pericarpium Citri Reticulatae 10-15 part, Semen Raphani 15-25 part, Radix Astragali 30-50 part, Endothelium Corneum Gigeriae Galli 120-150 part, Rhizoma Atractylodis Macrocephalae 130-140 part processed, Polyporus 30-50 part, Fructus Mume 20-40 part, Radix Et Rhizoma Rhei 5-8 part, Rhizoma Cyperi 20-40 part, Cortex Ilicis Rotundae 60-80 part, Radix Glycyrrhizae 20-30 part and Fructus Jujubae 200-400 part.
Preferably, the Chinese medicine composition for the treatment of gastrointestinal disease of the present invention comprises the material of following weight portion: Os Sepiae 150 parts, Rhizoma Corydalis processed 130 parts, Rhizoma Cimicifugae 12 parts, Radix Dichroae 8 parts, Fructus Hordei Germinatus (parched to brown) 35 parts, Fructus Crataegi (parched to brown) 35 parts, Massa Medicata Fermentata (parched to brown) 35 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 parts, Pollen Pini 220 parts, Fructus Amomi 18 parts, Radix Notoginseng 10 parts, 15 parts, Poria, roud cardamon seed 30 parts, Pericarpium Citri Reticulatae 12 parts, Semen Raphani 20 parts, the Radix Astragali 40 parts, Endothelium Corneum Gigeriae Galli 130 parts, the Rhizoma Atractylodis Macrocephalae processed 135 parts, Polyporus 40 parts, Fructus Mume 30 parts, Radix Et Rhizoma Rhei 6 parts, Rhizoma Cyperi 30 parts, Cortex Ilicis Rotundae 70 parts, 25 parts, Radix Glycyrrhizae and 300 parts, Fructus Jujubae.
More preferably, the Chinese medicine composition for the treatment of gastrointestinal disease of the present invention also comprises the material of following weight portion: Radix Semiaquilegiae 25 parts, Herba Liparidis nervosae 20 parts, Radix Bauhiniae Hupehanae 20 parts, Herba Stachytarphetae Jamaicensis 15 parts, Radix et Caulis Opuntiae Dillenii 20 parts, Caulis et Folium Brassicae capitatae 20 parts, Herba Fimbristylis dichotomae 15 parts, Parmelia tinctorum Despr. 10 parts, Herba Cynanchi Thesioidis 15 parts, Radix seu Caulis Verntilaginis Leiocarpae 10 parts, Flos daphnes odorae 10 parts and Taxillus caloreas (Diels) Danser 10 parts.
Most preferably, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
The present invention also provides the purposes of compositions in the Chinese medicine of preparation treatment gastrointestinal disease, described compositions comprises the material of following weight portion: Os Sepiae 120-180 part, Rhizoma Corydalis 120-150 part processed, Rhizoma Cimicifugae 10-15 part, Radix Dichroae 6-10 part, Fructus Hordei Germinatus (parched to brown) 30-45 part, Fructus Crataegi (parched to brown) 30-45 part, Massa Medicata Fermentata (parched to brown) 30-45 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 10-18 part, Pollen Pini 200-250 part, Fructus Amomi 15-20 part, Radix Notoginseng 8-15 part, Poria 10-18 part, roud cardamon seed 20-35 part, Pericarpium Citri Reticulatae 10-15 part, Semen Raphani 15-25 part, Radix Astragali 30-50 part, Endothelium Corneum Gigeriae Galli 120-150 part, Rhizoma Atractylodis Macrocephalae 130-140 part processed, Polyporus 30-50 part, Fructus Mume 20-40 part, Radix Et Rhizoma Rhei 5-8 part, Rhizoma Cyperi 20-40 part, Cortex Ilicis Rotundae 60-80 part, Radix Glycyrrhizae 20-30 part and Fructus Jujubae 200-400 part.
Preferably, described compositions comprises the material of following weight portion: Os Sepiae 150 parts, Rhizoma Corydalis processed 130 parts, Rhizoma Cimicifugae 12 parts, Radix Dichroae 8 parts, Fructus Hordei Germinatus (parched to brown) 35 parts, Fructus Crataegi (parched to brown) 35 parts, Massa Medicata Fermentata (parched to brown) 35 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 parts, Pollen Pini 220 parts, Fructus Amomi 18 parts, Radix Notoginseng 10 parts, 15 parts, Poria, roud cardamon seed 30 parts, Pericarpium Citri Reticulatae 12 parts, Semen Raphani 20 parts, the Radix Astragali 40 parts, Endothelium Corneum Gigeriae Galli 130 parts, the Rhizoma Atractylodis Macrocephalae processed 135 parts, Polyporus 40 parts, Fructus Mume 30 parts, Radix Et Rhizoma Rhei 6 parts, Rhizoma Cyperi 30 parts, Cortex Ilicis Rotundae 70 parts, 25 parts, Radix Glycyrrhizae and 300 parts, Fructus Jujubae.
More preferably, described compositions also comprises the material of following weight portion: Radix Semiaquilegiae 25 parts, Herba Liparidis nervosae 20 parts, Radix Bauhiniae Hupehanae 20 parts, Herba Stachytarphetae Jamaicensis 15 parts, Radix et Caulis Opuntiae Dillenii 20 parts, Caulis et Folium Brassicae capitatae 20 parts, Herba Fimbristylis dichotomae 15 parts, Parmelia tinctorum Despr. 10 parts, Herba Cynanchi Thesioidis 15 parts, Radix seu Caulis Verntilaginis Leiocarpae 10 parts, Flos daphnes odorae 10 parts and Taxillus caloreas (Diels) Danser 10 parts.
Most preferably, described Chinese medicine can be tablet, dispersible tablet, capsule, pill or decoction.
In the present invention, unit processed acts like a bully vinegar Rhizoma Corydalis.
The Rhizoma Atractylodis Macrocephalae processed is: get crude drug, and removing impurity, cleans, run through, cut sheet, dry.Be sprinkled into by wheat bran in hot pot, add Rhizoma Atractylodis Macrocephalae sheet in time smoldering, fry to yellowish-brown, effusion burnt odor gas, take out, sieve removes wheat bran.Every 100kg Rhizoma Atractylodis Macrocephalae sheet, uses wheat bran 10kg.
Chinese medicine composition of the present invention interacts, and synergism is evident in efficacy, highly widelys popularize.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment 1 decoction of the present invention
Take Os Sepiae 150 grams, Rhizoma Corydalis processed 130 grams, Rhizoma Cimicifugae 12 grams, Radix Dichroae 8 grams, Fructus Hordei Germinatus (parched to brown) 35 grams, Fructus Crataegi (parched to brown) 35 grams, Massa Medicata Fermentata (parched to brown) 35 grams, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 grams, Pollen Pini 220 grams, Fructus Amomi 18 grams, Radix Notoginseng 10 grams, 15 grams, Poria, roud cardamon seed 30 grams, Pericarpium Citri Reticulatae 12 grams, Semen Raphani 20 grams, the Radix Astragali 40 grams, Endothelium Corneum Gigeriae Galli 130 grams, the Rhizoma Atractylodis Macrocephalae processed 135 grams, Polyporus 40 grams, Fructus Mume 30 grams, Radix Et Rhizoma Rhei 6 grams, Rhizoma Cyperi 30 grams, Cortex Ilicis Rotundae 70 grams, 25 grams, Radix Glycyrrhizae and 300 grams, Fructus Jujubae, add 12000 ml waters, heating 5 hours under the condition of backflow, filter, filtrate is made to be cooled to room temperature, adding dehydrated alcohol to alcohol content is 60 volume %, hold over night, filter, ethanol in filtrate is reclaimed completely and get final product.
Embodiment 2 decoction of the present invention
Take Os Sepiae 150 grams, Rhizoma Corydalis processed 130 grams, Rhizoma Cimicifugae 12 grams, Radix Dichroae 8 grams, Fructus Hordei Germinatus (parched to brown) 35 grams, Fructus Crataegi (parched to brown) 35 grams, Massa Medicata Fermentata (parched to brown) 35 grams, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 grams, Pollen Pini 220 grams, Fructus Amomi 18 grams, Radix Notoginseng 10 grams, 15 grams, Poria, roud cardamon seed 30 grams, Pericarpium Citri Reticulatae 12 grams, Semen Raphani 20 grams, the Radix Astragali 40 grams, Endothelium Corneum Gigeriae Galli 130 grams, the Rhizoma Atractylodis Macrocephalae processed 135 grams, Polyporus 40 grams, Fructus Mume 30 grams, Radix Et Rhizoma Rhei 6 grams, Rhizoma Cyperi 30 grams, Cortex Ilicis Rotundae 70 grams, 25 grams, Radix Glycyrrhizae, 300 grams, Fructus Jujubae, Radix Semiaquilegiae 25 grams, Herba Liparidis nervosae 20 grams, Radix Bauhiniae Hupehanae 20 grams, Herba Stachytarphetae Jamaicensis 15 grams, Radix et Caulis Opuntiae Dillenii 20 grams, Caulis et Folium Brassicae capitatae 20 grams, Herba Fimbristylis dichotomae 15 grams, Parmelia tinctorum Despr. 10 grams, Herba Cynanchi Thesioidis 15 grams, Radix seu Caulis Verntilaginis Leiocarpae 10 grams, Flos daphnes odorae 10 grams and Taxillus caloreas (Diels) Danser 10 grams, add 12000 ml waters, heating 5 hours under the condition of backflow, filter, filtrate is made to be cooled to room temperature, adding dehydrated alcohol to alcohol content is 60 volume %, hold over night, filter, ethanol in filtrate is reclaimed completely and get final product.
Experimental example
Diagnostic criteria
1. acute onset.2. have and vomit in various degree.3. suffer from diarrhoea, yellow watery stool, does not have obvious mucus and pus and blood.4. with stomachache in various degree, paroxysmal colic can be shown as more.5. some patients is with heating, occurs the de-performance such as water and rock-soil coupling and acid base imbalance.6. stool routine examination can have leukocyte, blood leukocytes increases.7. abdominal part of having a medical check-up can have light tenderness, bowel sound hyperaction.8. Chinese medical discrimination is stagnation of cold-damp person.
Selector close standard of stating patient 120 example, wherein man 60 example, female 60 example, patient age 19-46 year, the mean age be (26.3 ± 1.2) year, the course of disease 3 hours-1 day.Be two groups by patient, be respectively treatment group 1 and treatment group 2, often group has 60 routine patients.Two groups of Genders, age, the course of disease, symptom there are no significant difference, have comparability (P > 0.05).
Treatment group 1 uses the decoction of preparation in embodiment 1 to treat, every day twice, at every turn oral 30 milliliters of decoctions, continuously treatment 3 days.
Treatment group 2 uses the decoction of preparation in embodiment 2 to treat, every day twice, at every turn oral 30 milliliters of decoctions, continuously treatment 3 days.
Criterion of therapeutical effect
Stool is normal, and vomiting disappears, other transference cures, and laboratory indexes detection display is normal, is recovery from illness; Times of defecation obviously reduces, approximate shaping, and vomiting waits other symptoms to improve, and laboratory indexes detects and is obviously improved as improvement; Symptom has no obvious improvement, and laboratory indexes is invalid without being improved as.
Statistical method
Utilize SPSS 13.0 software to process and analyze to experimental data, measurement data is with mean ± standard deviation
represent, adopt t inspection, enumeration data adopts x
2inspection, P < 0.05 represents that difference has statistical significance.
Result
Through treatment, for treatment group 1, recovery from illness 28 example, take a turn for the better 25 examples, invalid 7 examples, and total effective rate is 88.3%, and for treatment group 2, recovery from illness 39 example, take a turn for the better 20 examples, and invalid 1 example, total effective rate is 98.3%.Two groups of total effective rate comparing differences have statistical significance (P < 0.05).The effect for the treatment of group 2 is better than the effect for the treatment of group 1.
Untoward reaction and toxic and side effects supervision
Untoward reaction is judged by the clinical symptoms such as blood pressure, pulse detecting patient.Find that the systolic pressure of all patients is between 90-140mmHg, diastolic pressure is between 60-90mmHg, and pulse is 60-100 beat/min, and blood pressure and pulse is all within normal range.This illustrates that pharmaceutical composition of the present invention does not have obvious untoward reaction, and then proves that medicine does not have obvious toxic and side effects for human body.
Claims (8)
1. treat the Chinese medicine composition of gastrointestinal disease for one kind, it is characterized in that, it comprises the material of following weight portion: Os Sepiae 120-180 part, Rhizoma Corydalis 120-150 part processed, Rhizoma Cimicifugae 10-15 part, Radix Dichroae 6-10 part, Fructus Hordei Germinatus (parched to brown) 30-45 part, Fructus Crataegi (parched to brown) 30-45 part, Massa Medicata Fermentata (parched to brown) 30-45 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 10-18 part, Pollen Pini 200-250 part, Fructus Amomi 15-20 part, Radix Notoginseng 8-15 part, Poria 10-18 part, roud cardamon seed 20-35 part, Pericarpium Citri Reticulatae 10-15 part, Semen Raphani 15-25 part, Radix Astragali 30-50 part, Endothelium Corneum Gigeriae Galli 120-150 part, Rhizoma Atractylodis Macrocephalae 130-140 part processed, Polyporus 30-50 part, Fructus Mume 20-40 part, Radix Et Rhizoma Rhei 5-8 part, Rhizoma Cyperi 20-40 part, Cortex Ilicis Rotundae 60-80 part, Radix Glycyrrhizae 20-30 part and Fructus Jujubae 200-400 part.
2. the Chinese medicine composition for the treatment of gastrointestinal disease according to claim 1, it is characterized in that, it comprises the material of following weight portion: Os Sepiae 150 parts, Rhizoma Corydalis processed 130 parts, Rhizoma Cimicifugae 12 parts, Radix Dichroae 8 parts, Fructus Hordei Germinatus (parched to brown) 35 parts, Fructus Crataegi (parched to brown) 35 parts, Massa Medicata Fermentata (parched to brown) 35 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 parts, Pollen Pini 220 parts, Fructus Amomi 18 parts, Radix Notoginseng 10 parts, 15 parts, Poria, roud cardamon seed 30 parts, Pericarpium Citri Reticulatae 12 parts, Semen Raphani 20 parts, the Radix Astragali 40 parts, Endothelium Corneum Gigeriae Galli 130 parts, the Rhizoma Atractylodis Macrocephalae processed 135 parts, Polyporus 40 parts, Fructus Mume 30 parts, Radix Et Rhizoma Rhei 6 parts, Rhizoma Cyperi 30 parts, Cortex Ilicis Rotundae 70 parts, 25 parts, Radix Glycyrrhizae and 300 parts, Fructus Jujubae.
3. the Chinese medicine composition for the treatment of gastrointestinal disease according to claim 1 and 2, it is characterized in that, it also comprises the material of following weight portion: Radix Semiaquilegiae 25 parts, Herba Liparidis nervosae 20 parts, Radix Bauhiniae Hupehanae 20 parts, Herba Stachytarphetae Jamaicensis 15 parts, Radix et Caulis Opuntiae Dillenii 20 parts, Caulis et Folium Brassicae capitatae 20 parts, Herba Fimbristylis dichotomae 15 parts, Parmelia tinctorum Despr. 10 parts, Herba Cynanchi Thesioidis 15 parts, Radix seu Caulis Verntilaginis Leiocarpae 10 parts, Flos daphnes odorae 10 parts and Taxillus caloreas (Diels) Danser 10 parts.
4. the Chinese medicine composition for the treatment of gastrointestinal disease according to claim 3, is characterized in that, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
5. the purposes of compositions in the Chinese medicine of preparation treatment gastrointestinal disease, it is characterized in that, described compositions comprises the material of following weight portion: Os Sepiae 120-180 part, Rhizoma Corydalis 120-150 part processed, Rhizoma Cimicifugae 10-15 part, Radix Dichroae 6-10 part, Fructus Hordei Germinatus (parched to brown) 30-45 part, Fructus Crataegi (parched to brown) 30-45 part, Massa Medicata Fermentata (parched to brown) 30-45 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 10-18 part, Pollen Pini 200-250 part, Fructus Amomi 15-20 part, Radix Notoginseng 8-15 part, Poria 10-18 part, roud cardamon seed 20-35 part, Pericarpium Citri Reticulatae 10-15 part, Semen Raphani 15-25 part, Radix Astragali 30-50 part, Endothelium Corneum Gigeriae Galli 120-150 part, Rhizoma Atractylodis Macrocephalae 130-140 part processed, Polyporus 30-50 part, Fructus Mume 20-40 part, Radix Et Rhizoma Rhei 5-8 part, Rhizoma Cyperi 20-40 part, Cortex Ilicis Rotundae 60-80 part, Radix Glycyrrhizae 20-30 part and Fructus Jujubae 200-400 part.
6. purposes according to claim 5, it is characterized in that, described compositions comprises the material of following weight portion: Os Sepiae 150 parts, Rhizoma Corydalis processed 130 parts, Rhizoma Cimicifugae 12 parts, Radix Dichroae 8 parts, Fructus Hordei Germinatus (parched to brown) 35 parts, Fructus Crataegi (parched to brown) 35 parts, Massa Medicata Fermentata (parched to brown) 35 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 parts, Pollen Pini 220 parts, Fructus Amomi 18 parts, Radix Notoginseng 10 parts, 15 parts, Poria, roud cardamon seed 30 parts, Pericarpium Citri Reticulatae 12 parts, Semen Raphani 20 parts, the Radix Astragali 40 parts, Endothelium Corneum Gigeriae Galli 130 parts, the Rhizoma Atractylodis Macrocephalae processed 135 parts, Polyporus 40 parts, Fructus Mume 30 parts, Radix Et Rhizoma Rhei 6 parts, Rhizoma Cyperi 30 parts, Cortex Ilicis Rotundae 70 parts, 25 parts, Radix Glycyrrhizae and 300 parts, Fructus Jujubae.
7. the purposes according to claim 5 or 6, it is characterized in that, described compositions also comprises the material of following weight portion: Radix Semiaquilegiae 25 parts, Herba Liparidis nervosae 20 parts, Radix Bauhiniae Hupehanae 20 parts, Herba Stachytarphetae Jamaicensis 15 parts, Radix et Caulis Opuntiae Dillenii 20 parts, Caulis et Folium Brassicae capitatae 20 parts, Herba Fimbristylis dichotomae 15 parts, Parmelia tinctorum Despr. 10 parts, Herba Cynanchi Thesioidis 15 parts, Radix seu Caulis Verntilaginis Leiocarpae 10 parts, Flos daphnes odorae 10 parts and Taxillus caloreas (Diels) Danser 10 parts.
8. purposes according to claim 7, is characterized in that, described Chinese medicine can be tablet, dispersible tablet, capsule, pill or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510502780.4A CN104998185A (en) | 2015-08-17 | 2015-08-17 | Traditional Chinese medicine composition for treating gastrointestinal disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510502780.4A CN104998185A (en) | 2015-08-17 | 2015-08-17 | Traditional Chinese medicine composition for treating gastrointestinal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104998185A true CN104998185A (en) | 2015-10-28 |
Family
ID=54371221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510502780.4A Pending CN104998185A (en) | 2015-08-17 | 2015-08-17 | Traditional Chinese medicine composition for treating gastrointestinal disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104998185A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822767A (en) * | 2017-04-20 | 2017-06-13 | 石家庄肾病医院股份有限公司 | A kind of Chinese medicine composition and its application method for treating the stomach trouble that uremia causes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202006004872U1 (en) * | 2006-03-10 | 2006-07-20 | Icb Investment Consulting Und Beteiligungen Gmbh | Agents, useful for therapeutic purposes, comprising Cistus plant extract, vitamin E and optionally active agents, vitamins, minerals and/or usual formulation auxiliary agents |
| CN104547125A (en) * | 2014-12-29 | 2015-04-29 | 于海华 | Gastrointestinal drug and application thereof |
-
2015
- 2015-08-17 CN CN201510502780.4A patent/CN104998185A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202006004872U1 (en) * | 2006-03-10 | 2006-07-20 | Icb Investment Consulting Und Beteiligungen Gmbh | Agents, useful for therapeutic purposes, comprising Cistus plant extract, vitamin E and optionally active agents, vitamins, minerals and/or usual formulation auxiliary agents |
| CN104547125A (en) * | 2014-12-29 | 2015-04-29 | 于海华 | Gastrointestinal drug and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 姬孝斌: "功能性消化不良的中医治疗", 《现代中医药》 * |
| 王绪前等: "《中药材彩色图谱》", 31 May 2015 * |
| 龙运光等: "《中国侗族医药 下》", 30 June 2014 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822767A (en) * | 2017-04-20 | 2017-06-13 | 石家庄肾病医院股份有限公司 | A kind of Chinese medicine composition and its application method for treating the stomach trouble that uremia causes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100408067C (en) | Chinese medicines for stomach pain due to Qi stagnation and its preparing method | |
| CN109674958A (en) | A kind of Chinese medicine composition and its preparation method and application with anti-trioxypurine | |
| CN102872261A (en) | Application of straw berry tomato in preparing medicine for treating acute cholecystitis | |
| CN103301400A (en) | Traditional Chinese medicinal composition for treating chronic atrophic gastritis and preparation method of traditional Chinese medicinal composition | |
| CN107095995B (en) | A pharmaceutical composition for treating gastritis and gastric ulcer, and its preparation method | |
| CN112057553A (en) | Uric acid reducing composition and preparation method and application thereof | |
| CN105943953A (en) | Health product for treating diabetes and preparation method thereof | |
| CN110404045A (en) | A kind of Chinese medicine preparation and preparation method thereof for treating constipation | |
| CN104998185A (en) | Traditional Chinese medicine composition for treating gastrointestinal disease | |
| CN102335370B (en) | Flavored medicinal composition for removing stasis and dredging collaterals, and preparation method thereof | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN101011457A (en) | Traditional Chinese medicine composition with immunological enhancement function | |
| CN104547683B (en) | A kind of Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN103585206B (en) | A kind of preparation method of Chrysosplenium extract and application thereof | |
| CN112755168A (en) | Traditional Chinese medicine preparation for treating chronic gastritis caused by helicobacter pylori and preparation method and application thereof | |
| CN105396017A (en) | Traditional Chinese medicine preparation used for treating fatty liver, and preparation method thereof | |
| CN101045116B (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN105169233B (en) | A kind of Chinese medicine composition for treating calculus | |
| CN103585537A (en) | Traditional Chinese medicine composition for treating diarrhea | |
| CN114732883B (en) | Traditional Chinese medicine composition for strengthening spleen and tonifying stomach as well as preparation method and application thereof | |
| CN111759901B (en) | Traditional Chinese medicine composition for treating functional abdominal pain of children and preparation method thereof | |
| CN107158268A (en) | It is a kind of to treat Chinese medicine composition of hypertension and its preparation method and application | |
| CN1331527C (en) | Traditional Chinese medicinal prepn. for treating chronic prostatitis and prostatauxe, and its prepn. method | |
| CN104644886A (en) | Traditional Chinese medicine for treating viral myocarditis and preparation method of traditional Chinese medicine | |
| CN104524540A (en) | Traditional Chinese medicine composition for treating gallbladder polyps |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151028 |